156 related articles for article (PubMed ID: 34677242)
1. Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14).
Martel-Lafay I; Monnet I; Lardy-Cleaud A; Danhier S; Salem N; Gallocher O; Fournel P; Chouaid C; Bylicki O; The Gfpc-Investigators
Curr Oncol; 2021 Sep; 28(5):3804-3811. PubMed ID: 34677242
[TBL] [Abstract][Full Text] [Related]
2. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.
Nantavithya C; Gomez DR; Wei X; Komaki R; Liao Z; Lin SH; Jeter M; Nguyen QN; Li H; Zhang X; Poenisch F; Zhu XR; Balter PA; Feng L; Choi NC; Mohan R; Chang JY
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):558-563. PubMed ID: 29680255
[TBL] [Abstract][Full Text] [Related]
4. The impact of histology in the outcomes of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) and adjuvant chemotherapy.
Ernani V; Appiah AK; Baine MJ; Smith LM; Ganti AK
Cancer Treat Res Commun; 2020; 24():100197. PubMed ID: 32777751
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer.
Cong Y; Sun B; Wang J; Meng X; Xuan L; Zhang J; Liu J; Shen G; Wu S
Thorac Cancer; 2019 Jul; 10(7):1567-1575. PubMed ID: 31187604
[TBL] [Abstract][Full Text] [Related]
6. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
[TBL] [Abstract][Full Text] [Related]
8. Salvage Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Primary Surgical Resection of Non-small-cell Lung Cancer.
Sittenfeld SMC; Juloori A; Reddy CA; Stephans KL; Videtic GMM
Clin Lung Cancer; 2021 May; 22(3):e360-e365. PubMed ID: 32624412
[TBL] [Abstract][Full Text] [Related]
9. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
10. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
[TBL] [Abstract][Full Text] [Related]
11. Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 Trial.
Heinzerling JH; Pen OV; Robinson M; Foster R; Kelly B; Mileham KF; Moeller B; Prabhu RS; Corso C; Ward MW; Sullivan CM; Burri S; Simone CB
Pract Radiat Oncol; 2023; 13(6):531-539. PubMed ID: 37406774
[TBL] [Abstract][Full Text] [Related]
12. A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of a prospective French study.
Claude L; Morelle M; Mahé MA; Pasquier D; Boisselier P; Bondiau PY; Touboul E; Peignaux-Casasnovas K; Martel-Lafay I; Gassa F; Perrier L; Dussart S; Beckendorf V
Br J Radiol; 2020 Dec; 93(1116):20200256. PubMed ID: 32970478
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.
Singh AK; Hennon M; Ma SJ; Demmy TL; Picone A; Dexter EU; Nwogu C; Attwood K; Tan W; Hermann GM; Fung-Kee-Fung S; Malhotra HK; Yendamuri S; Gomez-Suescun JA
BMC Cancer; 2018 Nov; 18(1):1183. PubMed ID: 30497431
[TBL] [Abstract][Full Text] [Related]
15. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
16. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review.
Allignet B; De Ruysscher D; Martel-Lafay I; Waissi W
Cancer Treat Rev; 2023 Jul; 118():102573. PubMed ID: 37210766
[TBL] [Abstract][Full Text] [Related]
18. Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment.
Tubin S; Khan MK; Salerno G; Mourad WF; Yan W; Jeremic B
Radiat Oncol; 2019 Nov; 14(1):212. PubMed ID: 31771654
[TBL] [Abstract][Full Text] [Related]
19. Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance.
Spratt DE; Wu AJ; Adeseye V; Din SU; Shaikh F; Woo KM; Zhang Z; Foster A; Rosenzweig KE; Gewanter R; Huang J; Rimner A
Clin Lung Cancer; 2016 May; 17(3):177-183.e2. PubMed ID: 26602271
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients.
Dworzecki T; Idasiak A; Syguła D; Dworzecka U; Suwiński R
Neoplasma; 2012; 59(1):114-20. PubMed ID: 22103905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
